Table 2.
Desensitization therapies [6]a
| Therapy | Dose | Frequency |
|---|---|---|
| PP | (A, F) 1.5 volume exchanges | (A) 5 consecutive days |
| (B) 5 times, every other day | ||
| (C) 2–3 times/week until transplant | ||
| (D) 5 times, every other day, every 2–4 weeks | ||
| IVIG | (A, B) 2 g/kg IV divided over 2 days | (A) every 2–4 weeks |
| (C) 2–3 g/kg IV divided over 4 days | (D) every 2–4 weeks | |
| (D) 0.1 mg/kg IV | (G) every 4 weeks | |
| (E) 100 mg/kg IV | ||
| (f) 20 g (of 10% IVIG) | ||
| (G) 150 g (of 10% IVIG) divided over 3 rounds | ||
| Rituximab | (A) 1 g IV | (A) weekly × 4 |
| (C) 375 mg/m2 | (C) × 2 doses | |
| (G) 500 mg | (G) every 2 weeks | |
| Cyclophosphamide (used in the past) | (A) 1 mg/kg orally | (A) daily |
| (c) 0.5 µg/m2 | ||
| (D) 1 mg/kg orally |
A = UCLA; B = Stanford University; C = University of Maryland; D = University of Toronto; E = University of Wisconsin; F = Loyola University Chicago; G = University of Berlin.
a
Choices to consider as desensitization therapies include IVIG infusion, PP, either alone or combined, Rituximab, and in very selected cases, splenectomy.